Johnson & Johnson (NYSE:JNJ) on Friday announced plans to boost its U.S. investments to more than $55B over the next four ...

Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing ...

Johnson Johnson (NYSE: JNJ) announced plans to invest over $55 billion in the United States over the next four years, ...

Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...

Today, Johnson & Johnson (NYSE: JNJ) (the "Company"), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of ...

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American ...

强生公司 (NYSE: JNJ )宣布，美国食品药品监督管理局 (FDA) 已授予 posdinemab 快速通道资格，posdinemab 是一种针对磷酸化 tau 的单克隆抗体 ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic ...

周三，RBC Capital Markets维持强生公司（NYSE:JNJ）"跑赢大市"评级，目标价保持在$181.00。该机构的分析是在强生公司最近的分析师会议之后做出的，会议重点介绍了在美国皮肤科学会（AAD）年会上展示的Icotrokinra（JNJ-2113）研究数据。 公司估计Icotrokinra的年度销售机会可能超过$50亿。预计该药物将在强生公司创新医药业务的增长中发挥重要作用，有 ...

宾夕法尼亚州斯普林豪斯讯 - 强生公司（NYSE: ...